US 6156303A
· Russell et al.
· 2000
[cited by applicant]
US 7282199B2
· Gao et al.
· 2007
[cited by applicant]
EP 3749771
· 2020
[cited by applicant]
WO WO03042397
· 2003
[cited by applicant]
WO WO2005033321A2
· 2005
[cited by applicant]
WO WO2008088895A2
· 2008
[cited by applicant]
WO WO2016177911
· 2016
[cited by applicant]
WO WO2019193119
· 2019
[cited by applicant]
Crawford et al., J Cell Biol (2000) 150(6): 1399-1410 (Year: 2000).
[cited by examiner]
Crawford et al., The Journal of Cell Biology (2000) 150: 1399-1409 (Year: 2000).
[cited by examiner]
Coley et al., “Effect of genetic background on the dystrophicphenotype in mdx mice”, Hum Mol Genet Jan. 1, 2016;25(1):130-45.
[cited by applicant]
Decrouy et al., “Mini-dystrophin gene transfer in mdx4cv diaphragmmuscle fibers increases sarcolemmal stability”, Gene Ther May 1997;4(5):401-8.
[cited by applicant]
Dumont et al., “Dystrophin expression in muscle stem cells regulatestheir polarity and asymmetric division”, Nat Med Dec. 2015;21(12):1455-63.
[cited by applicant]
Ervasti, “Dystrophin, its interactions with other proteins, andimplications for muscular dystrophy”, Biochim Biophys Acta Feb. 2007;1772(2):108-17.
[cited by applicant]
Foster et al., “Codon and mRNA sequence optimization ofmicrodystrophin transgenes improves expressionand physiological outcome in dystrophic mdx micefollowing AAV2/8 gene transfer”, Mol Ther Nov. 2008;16(11):1825-32.
[cited by applicant]
Jarmin et al., “New developments in the use of gene therapy to treatDuchenne muscular dystrophy”, Expert Opin Biol Ther. Feb. 2014;14(2):209-30.
[cited by applicant]
Kodippili et al., “Dual AAV Gene Therapy for Duchenne MuscularDystrophy with a 7-kb Mini-Dystrophin Gene in theCanine Model”, Hum Gene Ther. Mar. 2018;29(3):299-311.
[cited by applicant]
Koo et al., “Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDjdog”, J Gene Med. Sep. 2011;13(9):497-506.
[cited by applicant]
Lai et al., “Dystrophins carrying spectrin-like repeats 16 and 17anchor nNOS to the sarcolemma and enhanceexercise performance in a mouse model of musculardystrophy”, J Clin Invest. Mar. 2009;119(3):624-35.
[cited by applicant]
Lai et al., “Evidence for the failure of adeno-associated virusserotype 5 to package a viral genome > or = 8.2 kb”, Mol. Ther. Jan. 2010;18(1):75-9.
[cited by applicant]
Larcher et al., “Characterization of dystrophin deficient rats: a newmodel for Duchenne muscular dystrophy”, PLoS One Oct. 13, 2014;9(10):e110371.
[cited by applicant]
Le Guiner et al., “Forelimb treatment in a large cohort of dystrophicdogs supports delivery of a recombinant AAV forexon skipping in Duchenne patients”, Mol Ther. Nov. 2014;22(11):1923-35.
[cited by applicant]
Le Guiner et al., “Long-term microdystrophin gene therapy is effectivein a canine model of Duchenne muscular dystrophy”, Nat Commun. Jul. 25, 2017;8:16105.
[cited by applicant]
Moser. “Duchenne muscular dystrophy: pathogenetic aspectsand genetic prevention”, Hum Genet. 1984;66(1):17-40.
[cited by applicant]
Muntoni et al., “Dystrophin and mutations: one gene, severalproteins, multiple phenotypes”, Lancet Neurol. Dec. 2003;2(12):731-40.
[cited by applicant]
Pryadkina et al., “A comparison of AAV strategies distinguishesoverlapping vectors for efficient systemic delivery ofthe 6.2 kb Dysferlin coding sequence”, Mol Ther Methods Clin Dev. Mar. 25, 2015;2:15009.
[cited by applicant]
Rodino-Klapac et al., “Update on the treatment of Duchenne musculardystrophy”, Curr Neurol Neurosci Rep. Mar. 2013;13(3):332.
[cited by applicant]
Wang et al., “Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes indifferent serotype capsids and their quantitation”, Hum Gene Ther Methods. Aug. 2012;23(4):225-33.
[cited by applicant]
Yamashita et al., “The 8th and 9th tandem spectrin-like repeats ofutrophin cooperatively form a functional unit tointeract with polarity-regulating kinase PAR-1b”, Biochem Biophys Res Commun. Jan. 1, 2010;391(1):812-7.
[cited by applicant]
Yue et al., “C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double knockout …
[cited by applicant]
Zhang et al., “Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy”, Human Molecular Genetics, vol. 22, No. 18, May 15, 2013 (May 15, 2013)…
[cited by applicant]
Zhang et al., “Novel Mini-Dystrophin Gene Dual Adena-Associated Virus Vectors Restore Neuronal Nitric Oxide Synthase Expression at the Sarcolemma”, Human Gene Therapy, vol. 23, No. 1, Jan. 1, 2012 (Jan. 1, 2012), pp. 98…
[cited by applicant]
Zheng et al., “Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy”, Mol Ther Feb. 2012;20(2):456-61.
[cited by applicant]
International Search Report issued in application No. PCT/EP2020/058372, dated Jun. 12, 2020.
[cited by applicant]